Policy | July 07, 2025
Dr. Jitendra Singh inaugurates 'National Biobank' at CSIR-IGIB
CSIR-IGIB advances indigenous CRISPR Trials on sickle cell anaemia, anti-microbial resistance, liver fibrosis and rare disorders
CSIR-IGIB advances indigenous CRISPR Trials on sickle cell anaemia, anti-microbial resistance, liver fibrosis and rare disorders
Over 100 million cartridges of rh-insulin supplied to Malaysian health ministry; 345,000+ patients served
The program will start with providing bTrastuzumab to cancer patients facing treatment delays due to budget constraints
Launches FSSAI’s inclusive campaign to stop obesity with multilingual, sign language outreach and multi-platform media engagement under Eat Right India programme
The NPPA has capped prices for 41 drug combinations including diabetes, cholesterol, and sleep disorder treatments
Approximately 35% of male cancer patients and 12% of female cancer patients at Paras Health were diagnosed with tobacco-related cancers
The company was awarded the insulins supply contract for a three-year period in 2022 through April 2025
Standalone profit from operations for the quarter were Rs. 162 crores
For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.
EBITDA before special items decreases to €4.08 billion (7.4%)
Subscribe To Our Newsletter & Stay Updated
